What are the real possibilities for genome editing and CRISPR/Cas9?

BioInformatics has become the preeminent leader in the market for commercial and VOC data, analysis and industry-wide opinions about the hottest topic in the life sciences: CRISPR/Cas9 technology. (See our complimentary report The CRISPR Toolbox.)

In the 2016 Life Science Global Lab Funding & Budget Outlook, we polled members of The Science Advisory Board and asked: “What do you think is the most exciting technological breakthrough on the horizon in your area of research – and why?” Over 20% of our respondents answered “CRISPR/Cas9” or “genome editing.”

See below from excerpts from our global panel (your customers) as they describe the possibilities of this powerful technique.

“What do you think is the most exciting technological breakthrough on the horizon in your area of research – and why?”

“I believe that the CRISPR/Cas9 technique will be implemented to be applied to many different biological questions, technical challenges and promising therapies.”

Staff Scientist
United Kingdom

“This genome editing tool has great therapeutic potential. With the help of CRISPR/Cas9, the genes underlying human diseases can be corrected in stem cells which can them be transplanted.”

Professor
United States

“It will enable us to edit with a extraordinary degree of accuracy the human genome and, once harnessed, will be a valuable tool in our therapeutic arsenal.”

Professor
Germany

crispr_450

“It will allow us to tackle research problems from a different angle, speed up research and open new possibilities.”

Post-Doctoral Fellow
United Kingdom

“CRISPR allows easier manipulation also in systems which were previously very difficult to manipulate. NGS allows a depth and breadth of readouts that makes insights possible that were unthinkable 20 years ago.”

Post-Doctoral Fellow
United States

“The versatility of the technique allows for some fascinating possibilities for tissue specific manipulation in diverse model systems.”

Professor
United States

“This is very exciting because it will provide the animal model of human diseases for the preclinical study of vaccines and drugs.”

Professor
United States

“It is especially important in plants, due to resistance to the imprecision of current transgenic technology and the relative unavailability of knockout technology compared to animal and fungal systems.”

Post-Doctoral Fellow
United States

“No more SNP chips or gene sequencing — just access an individual’s information in silico for data analysis.”

Staff Scientist (Pharma)
United States

“The ability to correct cellular defects via gene editing quickly and efficiently could revolutionise the personalisation of medicine. However, strong regulatory controls must be in place on global level to deter the improper use of this technology.”

Professor
United Kingdom

“I think it’s a excellent gene-editing technology which is the strongest innovation since PCR. It could accelerate the gene-therapy field and target crops and livestock.”

Professor
Malaysia

“The technologies would be the innovative tool especially for the researcher who has less familiar with conventional transgenic application.”

Lab Manager (Pharma)
India

“They have really empowered us with cutting edge tools to accelerate the pace of research. Scientists like me can monitor the genotype to phenotype correlations, select the biomarkers, design the intervention therapies in large scale and in short period of time. The dream of personalized medicines and quantity and quality of food for everyone in affordable ways, will come true!”

Staff Scientist
Japan

“It will lead to a greater understanding of diseases and allow researchers to test the efficacy and specificity of their product in very specific cell types.”

Staff Scientist (Pharma)
United States

Want to see more verbatim insights from The Science Advisory Board? Let us know!

About the Report: The 2016 Life Science Global Lab Funding & Budget Outlook is designed to support annual strategic planning at life science tools companies. BioInformatics LLC and its SDi division have covered the industry for decades and are uniquely qualified to conduct primary and secondary research and help senior executives plan for success. For more information, contact Zach French at [email protected] or at 703-778-3080 x19.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published.